These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 35447492)
1. Identification of degradation products in flumazenil using LC-Q-TOF/MS and NMR: Degradation pathway elucidation. Jiang J; Hu ZL; Boucetta H; Liu JM; Song M; Hang TJ; Lu YT J Pharm Biomed Anal; 2022 Jun; 215():114764. PubMed ID: 35447492 [TBL] [Abstract][Full Text] [Related]
2. Stability-indicating HPLC method development and structural elucidation of novel degradation products in posaconazole injection by LC-TOF/MS, LC-MS/MS and NMR. Yang Y; Zhu X; Zhang F; Li W; Wu Y; Ding L J Pharm Biomed Anal; 2016 Jun; 125():165-77. PubMed ID: 27023129 [TBL] [Abstract][Full Text] [Related]
3. Identification of degradation products of brivaracetam using liquid chromatography quadrupole time-of-flight tandem mass spectrometry: Degradation pathway elucidation. Xu K; Ning M; Li W; Dong H; Lu Y; Hang T; Song M Rapid Commun Mass Spectrom; 2024 Jan; 38(2):e9651. PubMed ID: 38124167 [TBL] [Abstract][Full Text] [Related]
4. Use of LC-MS/TOF, LC-MS(n), NMR and LC-NMR in characterization of stress degradation products: Application to cilazapril. Narayanam M; Sahu A; Singh S J Pharm Biomed Anal; 2015; 111():190-203. PubMed ID: 25890215 [TBL] [Abstract][Full Text] [Related]
5. Development of a Stability-Indicating Purity Method for Ubrogepant Through Stress Degradation Analysis, Extraction, and Characterization of Unidentified Degradation Products Using Flash Chromatography, NMR, IR, and LC-MS. Vanga NR; K VR; Ummiti K; Ratnakaram VN J AOAC Int; 2024 Oct; 107(5):761-773. PubMed ID: 38941508 [TBL] [Abstract][Full Text] [Related]
6. Potential degradation products of abemaciclib: Identification and structural characterization employing LC-Q/TOF-MS and NMR including mechanistic explanation. Kathar N; Rajput N; Jadav T; Sengupta P J Pharm Biomed Anal; 2024 Jan; 237():115762. PubMed ID: 37844364 [TBL] [Abstract][Full Text] [Related]
7. Stress degradation studies on lornoxicam using LC, LC-MS/TOF and LC-MSn. Modhave DT; Handa T; Shah RP; Singh S J Pharm Biomed Anal; 2011 Nov; 56(3):538-45. PubMed ID: 21757313 [TBL] [Abstract][Full Text] [Related]
8. Degradation kinetics and characterization of major degradants of binimetinib employing liquid chromatography-high resolution mass spectrometry. Rajput N; Soni F; Sahu AK; Jadav T; Sharma S; Sengupta P J Pharm Biomed Anal; 2022 Jun; 215():114753. PubMed ID: 35447490 [TBL] [Abstract][Full Text] [Related]
9. Validated stability indicating assay method of olaparib: LC-ESI-Q-TOF-MS/MS and NMR studies for characterization of its new hydrolytic and oxidative forced degradation products. Thummar M; Kuswah BS; Samanthula G; Bulbake U; Gour J; Khan W J Pharm Biomed Anal; 2018 Oct; 160():89-98. PubMed ID: 30075398 [TBL] [Abstract][Full Text] [Related]
10. Identification of forced degradation products of tamsulosin using liquid chromatography/electrospray ionization tandem mass spectrometry. Namdev D; Borkar RM; Raju B; Kalariya PD; Rahangdale VT; Gananadhamu S; Srinivas R J Pharm Biomed Anal; 2014 Jan; 88():245-55. PubMed ID: 24083958 [TBL] [Abstract][Full Text] [Related]
11. Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development. Stolarczyk EU; Rosa A; Kubiszewski M; Zagrodzka J; Cybulski M; Kaczmarek Ł Eur J Pharm Sci; 2017 Nov; 109():389-401. PubMed ID: 28865686 [TBL] [Abstract][Full Text] [Related]
12. LC and LC-MS/MS studies for identification and characterization of new degradation products of ibrutinib and elucidation of their degradation pathway. Mehta L; Naved T; Grover P; Bhardwaj M; Mukherjee D J Pharm Biomed Anal; 2021 Feb; 194():113768. PubMed ID: 33279300 [TBL] [Abstract][Full Text] [Related]
13. Characterization of degradation products and process-related impurity of sutezolid by liquid chromatography/electrospray ionization tandem mass spectrometry. Guo K; Zhang T; Wang Y; Jin B; Ma C J Pharm Biomed Anal; 2019 May; 169():196-207. PubMed ID: 30877931 [TBL] [Abstract][Full Text] [Related]
14. Characterization of seven new related impurities and forced degradation products of tetracaine hydrochloride and proposal of degradation pathway by UHPLC-Q-TOF-MS. Liu C; Luo Y; Tao Q; Hong L; Zeng S J Pharm Biomed Anal; 2023 Jan; 223():115116. PubMed ID: 36343535 [TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of degradation products of irbesartan using LC-MS/TOF, MS(n), on-line H/D exchange and LC-NMR. Shah RP; Sahu A; Singh S J Pharm Biomed Anal; 2010 Apr; 51(5):1037-46. PubMed ID: 20018473 [TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of major degradation products of Eprinomectin drug substance including degradation pathways using LC-HRMS and NMR. Adhikari S; Rustum AM J Pharm Biomed Anal; 2022 Jun; 215():114767. PubMed ID: 35447491 [TBL] [Abstract][Full Text] [Related]
17. Identification and structural characterization of hydrolytic degradation products of alvimopan by LC/QTOF/MS/MS and NMR studies. Baira SM; R S; Talluri MVNK J Pharm Biomed Anal; 2019 Feb; 165():399-409. PubMed ID: 30590338 [TBL] [Abstract][Full Text] [Related]
18. LC, LC-MS/TOF and MS(n) studies for the identification and characterization of degradation products of nelfinavir mesylate. Tiwari RN; Bonde CG J Pharm Biomed Anal; 2011 Jun; 55(3):435-45. PubMed ID: 21392920 [TBL] [Abstract][Full Text] [Related]
19. LC-MS/TOF, LC-MSn, on-line H/D exchange and LC-NMR studies on rosuvastatin degradation and in silico determination of toxicity of its degradation products: a comprehensive approach during drug development. Shah RP; Sahu A; Singh S Anal Bioanal Chem; 2013 Apr; 405(10):3215-31. PubMed ID: 23386001 [TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of urapidil stress degradation products by LC-Q-TOF-MS and NMR: Toxicity prediction of degradation products. Velip L; Dhiman V; Kushwah BS; Golla VM; Gananadhamu S J Pharm Biomed Anal; 2022 Mar; 211():114612. PubMed ID: 35101803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]